KR20160136777A - Composition for antiinflammatory and neurodegenerative diseases comprising ixeris dentata nakai extract - Google Patents
Composition for antiinflammatory and neurodegenerative diseases comprising ixeris dentata nakai extract Download PDFInfo
- Publication number
- KR20160136777A KR20160136777A KR1020150070767A KR20150070767A KR20160136777A KR 20160136777 A KR20160136777 A KR 20160136777A KR 1020150070767 A KR1020150070767 A KR 1020150070767A KR 20150070767 A KR20150070767 A KR 20150070767A KR 20160136777 A KR20160136777 A KR 20160136777A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- pharmaceutical composition
- active ingredient
- composition according
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Abstract
Description
The present invention relates to a composition for preventing or treating an anti-inflammatory and degenerative neurological disease, comprising an extract of Zygomycota.
Ixeris dentata is a perennial plant belonging to Asteraceae and widely used in folk remedies for sedation, hypnosis, fever, hematopoiesis, dryness, indigestion, pneumonia, hepatitis, contusions, boils and appetite stimulation. The main constituents of scabbard were aliphatics, triterpenoids and sesquiterpene glucoside. In addition, several studies have reported that physiological activity such as lipid lowering and hypoglycemia, and antioxidant effect in cell experiments, suggest that functional materials effective for suppressing obesity and antioxidation may be inherent in scabbard.
On the other hand, there are antioxidant enzymes that protect against reactive oxygen species in the body such as superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase (CAT), glutathione reductase and glutathione-S- transferase. However, The role of antioxidants in the human body due to substances, smoking, stress, etc., exceeds the defense system, leading to protein degradation and DNA damage
Therefore, synthetic materials such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) have been developed as antioxidants. However, studies on finding dietary antioxidants that are safe from nature have been actively carried out Become
Inflammation, on the other hand, is a defense mechanism to prevent damage to human tissues caused by infection, which involves symptoms such as development, fever and pain. If the inflammatory reaction is repeated for a long period of time, it can cause various chronic diseases such as neurodegenerative diseases and cancer.
Macrophages are involved in and regulate the production of inflammatory mediators such as nitric oxide (NO), prostaglandin (PG) and pro-inflammatory cytokines in the human immune response. These inflammatory mediators induce an inflammatory response and, if the host immune response does not respond appropriately, induce inflammatory diseases.
Korean Patent Laid-Open Publication No. 1020120011981 discloses a dermal extract having anti-inflammatory effect and a composition for external application for skin comprising the same, wherein the dermal extract increases the expression of hemeoxygenase-1 and sirtuin-1 It has an anti-inflammatory effect.
The present invention has been made in view of the above needs, and an object of the present invention is to provide an anti-inflammatory composition.
Another object of the present invention is to provide a composition for treating or preventing degenerative neurological diseases.
In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing or treating degenerative neurological diseases, comprising an extract of Zygomycetae as an active ingredient.
In one embodiment of the invention, the composition is preferably but not limited to weaken inductive nitrogen oxide synthesis (iNOS) and NO production.
In another embodiment of the present invention, the extract is preferably a crude extract, preferably an ethanol extract, but is not limited thereto.
In another embodiment of the present invention, the composition preferably inhibits microglial cell activity in microglial cells, but is not limited thereto.
In another embodiment of the present invention, the composition preferably inhibits TNF-alpha activity, but is not limited thereto.
The present invention also provides a food composition for alleviating neurodegenerative degeneration comprising an extract of Ascorbia sinensis as an active ingredient.
The present invention also provides a pharmaceutical composition for antiinflammation comprising an extract of Ascorbicus as an active ingredient.
In addition, the present invention provides a functional food composition for anti-inflammation, which comprises an extract of Ascorbia sinensis as an active ingredient.
In addition, the present invention provides a composition for antioxidation comprising an extract of Ascorbia sinensis as an active ingredient.
The pharmaceutical composition comprising the extract of the present invention as an active ingredient may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders , A coating agent, a swelling agent, a lubricant, a lubricant, or a flavoring agent.
The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
In addition, the present invention provides a food composition comprising the scabby extract.
The food composition according to the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meats, chocolates, foods, confectionery, pizza, ramen noodles, gums, ice cream, alcoholic beverages, vitamin complexes, .
The present invention provides a health functional food comprising the composition.
The present invention also provides the use of a composition comprising the above-mentioned extract of Guaranae as an active ingredient for the manufacture of a medicament or food for the prevention and treatment of degenerative neurological diseases. The composition of the present invention comprising the extract of Aspergillum scutellum as an active ingredient can be used for the preparation of medicines or foods for the prevention or treatment of diseases related to the prevention and treatment of degenerative neurological diseases.
The invention also provides a method for the prevention or treatment of inflammatory diseases, comprising administering to a mammal a therapeutically effective amount of scutellum extract.
The term "mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
As used herein, the term "therapeutically effective amount " refers to the amount of active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, This includes an amount that induces relief of the symptoms of the disease or disorder being treated. It will be apparent to those skilled in the art that the therapeutically effective dose and the number of administrations of the active ingredient of the present invention will vary depending on the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like.
The dose of the extract of Zygomycetum, an active ingredient in the pharmaceutical composition according to the present invention, may be 1 to 3 g per kg of body weight per day, depending on the patient's age, sex, symptom, administration method or preventive purpose . Dosage levels for patients exhibiting the specific symptoms may vary depending on the patient's body weight, age, sex, health condition, diet, time of administration, administration method, excretion rate, severity of disease, and the like.
In the therapeutic method of the present invention, the composition comprising the extract of the present invention as an active ingredient may be administered orally, rectally, intravenously, intraarterally, intraperitoneally, intramuscularly, intrasternally, transdermally, topically, Lt; / RTI >
The composition comprising the extract of Zygomycetum japonica extract according to the present invention can completely weaken the production of LPS-induced inducible NO synthase (iNOS) NO in BV-2 cells, and the expression of iNOS protein , And these results suggest that the extract of Zygomyksis can be used as an effective anti-inflammatory agent and a therapeutic agent for degenerative neurological diseases.
Figure 1 shows the inhibition of DPPH by Scutellariae Radix extract.
Figure 2 shows the cell viability (BV-2 cells) of Scutellariae Radix extract.
FIG. 3 is a graph showing the inhibition of NO production by the extract of Scarlet.
FIG. 4 is a graph showing LPS-dependent iNOS and COX expression of Scutellariae Radix extract.
FIG. 5 is a graph showing the degree of TNF-alpha (a) and IL-6 (b) in LPS-activated BV-2 of Scarabaeae extract.
FIG. 6 is a graph showing the effect of inhibiting the activity of NF-kB in the extract of Scutellariae Radix.
Hereinafter, the present invention will be described in detail with reference to Examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1:
The barnyard was purchased from Kyungdong market and 100 g of barnyard were extracted with 1 L of ethanol for 72 hours at room temperature.
Example 2; Antioxidant
The DPPH radical scavenging activity of the extract of the umbilical cord was obtained by adding 30 μL of the extract solution and 30 μL of the 60 μM DPPH solution dissolved in ethanol. The reaction was carried out at room temperature for 2 minutes, transferred to a capillary tube, and then subjected to ESR (electron spin resonance) PX 2300, JEOL, Japan). In this case, the measurement conditions of the ESR spectrophotometer were 336.5 ± 5 mT for the magnetic field, 5 mW for the microwave power, 9.41 GHz for the modulation frequency, and DPPH free radical scavenging activity (% ESR signal intensity of the control medium / ESR signal intensity of the control medium) X100 showed a DPPH radical scavenging activity of more than 20% at a concentration of 0.1 mg / mL and a DPPH radical scavenging activity of more than 80% at a concentration of 1 mg / (Fig. 1).
Example 3: Cell viability
In order to examine the effect of LPS and L. extract on cell survival in BV-2 cells stimulated with LPS, cell viability was measured by 3- [4,5-Dimethylthiazol-2-yl] -2,5-diphenyl-tetrazolium bromide ) Analysis method.
Cells (1 × 10 5 cells / ml) were seeded in a 96-well plate (180 μL), cultured in a CO2 incubator for more than 12 hours, and cultured for 24 hours. After culturing, the culture medium was removed, and 200 μL of the medium containing 0.5 mg / mL MTT was added, followed by incubation for 4 hours to reduce the MTT. After removing the culture medium, 100 μL of dimethylsulfoxide (DMSO) was added and the resulting formazone crystals were dissolved. The absorbance was measured at 540 nm using an ELISA reader. Cell viability was expressed as percentage (%) as compared with control.
As a result of cell viability measurement, it was confirmed that cell survival rate was not changed in all the experimental groups treated with LPS and umbagus extract alone or together (FIG. 2).
This indicates that the inflammation inducers LPS and Scutellariae Radix extract do not affect cell survival.
Example 4: LPS -Induced inhibition of NO production by the extracts of Scutellariae Radix
In order to analyze the anti - inflammatory effect of the extract of Aspergillus nigra, LPS, which is an inflammation inducer, was confirmed to be dependent on the concentration of NO produced in the glial cells stimulated by each concentration.
NO was determined by seeding 5 × 10 5 cells / well in a 24-well plate. LPS and extracts were added at different concentrations, and incubated for 24 h in a 24-h incubator. Griess reagent (1% sulfanilamide / After reacting with 0.1% N- (1-naphthyl) -ethylenediamine dihydrochloride / 2.5% H3PO4), the value is measured using a Sunrise basic 96-well microplate spectrophotometer (TECAN AUSTRIA) with a wavelength of 540 nm.
The amount of NO induced by LPS (1 / mL) in the glial cells was about 27 μM, which was about 20 times higher than that of 1 μM used as the control group. , and ug / mL, indicating that NO production was reduced in a concentration-dependent manner (Fig. 3).
Example 5: After treatment of scabies extracts in glial cells LPS Induced by iNOS inducible nitric oxide synthase ) Concentration-dependent inhibition of protein expression
Changes in iNOS protein expression patterns were determined after administration of the extract of Aspergillus oryzae. For protein expression immunoblot analysis, BV2 cells were identified by using a lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% NaN3) after washing the cells twice with 1 × PBS .
Proteins were quantitatively analyzed using the bradford method of the BCA assay kit (bio-rad CA). The same amount of protein was electrophoresed on 10% SDS-PAGE and then eluted with 0.45 μm polyvinylidene fluoride (PVDF: Millipore) The anti-iNOS and COX-2 were diluted 1/1000, the beta -actin was diluted 1/5000, the O / N was over-night at 4 ° C and the secondary antibody was used as the primary antibody. The antibody with Horseradish peroxidase (HRP) was reacted with supersignal (Pierce, CA) for 1 hour at room temperature, and the results were confirmed using LAS-3000 (Fuji Co, Japan).
Immunoblot analysis showed that the expression level of iNOS protein in the control group not treated with LPS was almost zero and the expression of iNOS protein in the experimental group treated with LPS was significantly increased. The expression patterns of the extracts decreased after the treatment with the extracts of Aspergillus oryzae . Beta-actin was used as a control for quantitative analysis of proteins (Fig. 4).
Example 6: TNF -Alpha Cytokine
TNF-alpha, a representative inflammatory cytokine, was measured in order to determine whether the extract was inhibited by inflammatory cytokines. TNF-alpha was measured by seeding 5 × 10 5 cells / well in a 24-well plate, adding LPS and extracts at different concentrations, reacting in a 24 h incubator, and then measuring using a kit. This confirms the effect of the extract on the TNF-alpha concentration. As shown in FIG. 5, TNF-alpha concentration, which is an inflammatory cytokine, was measured after LPS treatment, and TNF-alpha was significantly increased in the LPS-treated group, but it was decreased in the LPS-treated group. Thus, it was confirmed that the extract of Aspergillus japonicus reduced the inflammatory cytokine TNF-alpha in a dose-dependent manner (Fig. 5).
Example 7: Scarlet Extract NF - kB Activity inhibitory effect
In immunoblot, the expression level of NF-kB protein was significantly reduced in the control group without LPS treatment, and the expression of NF-kB protein was significantly increased in the LPS-treated experimental group. The expression patterns of the extracts decreased after the treatment with the extracts of Aspergillus oryzae . Beta-actin was used as a control for quantitative analysis of proteins (Fig. 6).
Claims (15)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150070767A KR20160136777A (en) | 2015-05-21 | 2015-05-21 | Composition for antiinflammatory and neurodegenerative diseases comprising ixeris dentata nakai extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150070767A KR20160136777A (en) | 2015-05-21 | 2015-05-21 | Composition for antiinflammatory and neurodegenerative diseases comprising ixeris dentata nakai extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160136777A true KR20160136777A (en) | 2016-11-30 |
Family
ID=57707426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150070767A KR20160136777A (en) | 2015-05-21 | 2015-05-21 | Composition for antiinflammatory and neurodegenerative diseases comprising ixeris dentata nakai extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160136777A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102266271B1 (en) * | 2019-12-09 | 2021-06-17 | 대한민국 | Composition for preventing or treating diabetes containing extract of Ixeris strigosa |
-
2015
- 2015-05-21 KR KR1020150070767A patent/KR20160136777A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102266271B1 (en) * | 2019-12-09 | 2021-06-17 | 대한민국 | Composition for preventing or treating diabetes containing extract of Ixeris strigosa |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Algenstaedt et al. | The effect of Morinda citrifolia L. fruit juice on the blood sugar level and other serum parameters in patients with diabetes type 2 | |
| Lorenzo et al. | Sources, chemistry, and biological potential of ellagitannins and ellagic acid derivatives | |
| EP3560506A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
| Rasheed | Ginger and its active constituents as therapeutic agents: Recent perspectives with molecular evidences | |
| US10286021B2 (en) | Composition for prevention or treatment of arthritis, containing Sargassum serratifolium extract as active ingredient | |
| KR20180106103A (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising arctium lappa l. extract | |
| KR101638258B1 (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising tetragonia tetragonoides extract | |
| KR20180080896A (en) | Pharmaceutical composition comprising ecklonia cava extract for treatment and prevention of antiinflammatory and inflammatory neurodegenerative diseases | |
| KR20190025289A (en) | A composition for antiinflammatory and inflammatory neurodegenerative diseases comprising jujube seed extract | |
| Saad | Greco-Arab and Islamic diet therapy: Tradition, research and practice | |
| KR20160136777A (en) | Composition for antiinflammatory and neurodegenerative diseases comprising ixeris dentata nakai extract | |
| KR20200063772A (en) | Composition for anti-inflammation comprising extract of mealworm containing ginsenoside Re | |
| KR20180080834A (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising hizikia fusiforme extract | |
| KR20180106105A (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising lycium barbarum extract | |
| KR101643048B1 (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising castanea crenata inner shell extract | |
| KR20180109156A (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising chaenomeles sinesis koehne extract | |
| KR20180106104A (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising ulmi cortex extract | |
| US20220062312A1 (en) | Oral composition comprising b-escin and the use thereof | |
| KR20180109297A (en) | Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising rubus coreanus extract | |
| KR20170068221A (en) | A composition for antioxidant and inflammatory neurodegenerative diseases comprising fagopyrum tataricum extract | |
| KR20160081189A (en) | Composition comprising an extract of Eisenia bicyclis for preventing and treating Alzheimers disease | |
| KR102621205B1 (en) | An anti-oxidant and anti-inflammatory composition comprising extracts of lacquer tree, fluafomitella fraxinea and kudingcha | |
| KR20130046094A (en) | Medical composition comprising abutilon avicennae extract for preventing or treating inflammatory disease | |
| KR102063779B1 (en) | Pharmaceutical composition for preventing or treating inflammatory disease comprising dudleya brittonii extract | |
| KR101923822B1 (en) | Anti-inflammatory composition containing extract of cornus officinalis seed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |